Protocol and establishment of a Queensland renal biopsy registry in Australia

Abstract

Background: Renal biopsy is often required to obtain information for diagnosis, management and prognosis of kidney disease that can be broadly classified into acute kidney injury (AKI) and chronic kidney disease (CKD). The most common conditions identified on renal biopsy are glomerulonephritis and tubulo-interstitial disorders. There is a paucity of information on management strategies and therapeutic outcomes in AKI and CKD patients. A renal biopsy registry will provide information on biopsy-proven kidney disorders to improve disease understanding and tracking, healthcare planning, patient care and outcomes.; Methods: A registry of patients, that includes biopsy-proven kidney disease, was established through the collaboration of nephrologists from Queensland Hospital and Health Services and pathologists from Pathology Queensland services. The registry is in keeping with directions of the Advancing Kidney Care 2026 Collaborative, established in September 2018 as a Queensland Health initiative. Phase 1 of the registry entailed retrospective acquisition of data from all adult native kidney biopsies performed in Queensland, Australia, from 2002 to 2018. Data were also linked with the existing CKD.QLD patient registry. From 2019 onwards, phase 2 of the registry involves prospective collection of all incident consenting patients referred to Queensland public hospitals and having a renal biopsy. Annual reports on patient outcomes will be generated and disseminated.; Discussion: Establishment of the Queensland Renal Biopsy Registry (QRBR) aims to provide a profile of patients with biopsy-proven kidney disease that will lead to better understanding of clinico-pathological association and facilitate future research. It is expected to improve patient care and outcomes.Nephrology (Carlton). 2016 Nov;21(11):916-922. (PMID: 27075933); Nephrology (Carlton). 2016 Jan;21(1):28-34. (PMID: 26154936); Kidney Int. 2004 Sep;66(3):890-4. (PMID: 15327376); BMC Nephrol. 2013 Oct 29;14:236. (PMID: 24168011); Clin Adv Hematol Oncol. 2016 Nov;14 Suppl 11(11):2-15. (PMID: 27930620); Clin Exp Nephrol. 2011 Aug;15(4):493-503. (PMID: 21437579); Autoimmun Rev. 2013 Oct;12(12):1129-35. (PMID: 23820041); Kidney Int. 2004 Sep;66(3):895-7. (PMID: 15327377); Clin J Am Soc Nephrol. 2008 May;3(3):674-81. (PMID: 18354075); Intern Med J. 2011 Mar;41(3):270-8. (PMID: 21426464); Kidney Int. 2010 Aug;78(4):337-42. (PMID: 20520593); Nephrology (Carlton). 2015 Dec;20(12):899-907. (PMID: 26096749); Nephrol Dial Transplant. 2004 Dec;19(12):3040-9. (PMID: 15507479); Kidney Dis (Basel). 2016 Oct;2(3):103-110. (PMID: 27921037); Nephrol Dial Transplant. 2002 Sep;17(9):1594-602. (PMID: 12198210); Kidney Int. 2005 May;67(5):1961-6. (PMID: 15840044); Nephrol Dial Transplant. 2001 Jul;16(7):1364-7. (PMID: 11427626); Nephrol Dial Transplant. 2016 Jun;31(6):971-7. (PMID: 25061125). Linking ISSN: 14712369. Subset: MEDLINE; Date of Electronic Publication: 2020 Aug 01. ; Original Imprints: Publication: London : BioMed Central, [2000- <br />